Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer - Candel Therapeutics (NASDAQ:CADL)

Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer - Candel Therapeutics (NASDAQ:CADL)

NEEDHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the European Medicines Agency (EMA) has granted Orphan Designation for CAN-2409 (aglatimagene besadenovec) for the treatment of pancreatic cancer. This designation complements CAN…

Candel Therapeutics' CAN-2409 gains EMA orphan designation

This approval follows the previous US Food and Drug Administration (FDA) recognitions, including orphan drug and fast track designations awarded in April 2024 and December 2023 to CAN-2409 The post Candel Therapeutics’ CAN-2409 gains EMA orphan designation appeared first on Pharmaceutical Business review.

Candel Therapeutics’ CAN-2409 Receives European Orphan Designation for Pancreatic Cancer Treatment

Candel Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced that the European Medicines Agency (EMA) has granted Orphan Designation for its drug CAN-2409, aimed at treating pancreatic cancer. This designation is a significant milestone for the company, as it complements the drug’s existing U.S. Food and Drug Administration (FDA) Orphan Drug Designation and FDA Fast Track Designation, underscoring the global recognition o…

Candel Therapeutics' CAN-2409 Receives European Orphan Designation for Pancreatic Cancer Treatment

Candel Therapeutics, Inc. has announced that the European Medicines Agency (EMA) has granted Orphan Designation to its investigational drug CAN-2409 for the treatment of pancreatic cancer, marking a significant milestone in the drug’s development and regulatory strategy. This designation, which complements similar recognitions from the U.S. Food and Drug Administration (FDA), underscores the drug’s potential to meet a critical need in treating o…

Candel Therapeutics Gets European Orphan Status for Pancreatic Cancer Drug CAN-2409

Candel Therapeutics, Inc.(Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the European Medicines Agency (EMA) has granted Orphan Designation for CAN-2409 (aglatimagene besadenovec) for the treatment of pancreatic cancer. This designation complements CAN-2409’s existing U.S. Food and Drug Administration (FDA) Orphan Drug Desig…